DUBLIN–(BUSINESS WIRE)–The “Oral Cancer Therapeutics Market by Product and Geography – Global Forecast and Analysis 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
Global Oral Cancer Therapeutics Market: About this market
Global oral cancer therapeutics market report looks at factors such as increasing incidence and prevalence of oral cancer, increasing risk factors for oral cancer, growing awareness about oral cancer. However, side-effects of chemotherapeutics, adoption of alternative treatment option as first-line therapy, high treatment cost targeted therapies may hamper the growth of the oral cancer therapeutics industry over the forecast period.
The oral cancer therapeutics market analysis considers sales from both targeted therapy and chemotherapy. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as encourage additional R&D investments and exploit interactions and technological capabilities will play a significant role in the targeted therapy segment to maintain its market position.
Global Oral Cancer Therapeutics Market: Overview
Growing awareness about oral cancer
Several public and private organizations are taking the initiative to increase awareness about oral cancer. These organization aims to raise awareness about the disease to get more mouth cancers diagnosed at an early stage. The organizations educate the mass about the risk factors, and signs and symptoms and encouraging them to discuss this with their dental professionals. CDC continues its effort to promote oral cancer research, surveillance and comprehensive educational sources for healthcare professionals and the public by increasing excise taxes on tobacco and alcohol products to targeted funding for oral cancer prevention program. This will lead to the expansion of the global oral cancer therapeutics market at a CAGR of over 8% during the forecast period.
Development of nanotechnology-based drug delivery systems
Targeted drug delivery systems by nanoparticles are expected to be the most promising multi-functional platform in cancer therapeutics. The emergence of nanoparticles in drug delivery provided solutions to many challenges such as enhanced and effective drug loading, transportation and controlled drug release, and precise targeting of tumor-sites. They also support in the development of toxic-free atmosphere by reducing the quantity of the drug to a concentration at the surrounding area of the targeted site making it more efficient. This development is expected to have a positive impact on the overall market growth.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Targeted therapy – Market size and forecast 2018-2023
- Chemotherapy – Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Increasing R&D of new drugs
- Development of nanotechnology-based drug delivery systems
- Patient assistance programs
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Mylan NV
- Pfizer Inc.
- Sanofi
-
Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/l6lrpi
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900